36.75 0.00 (0.00%)
After hours: 5:16PM EST
|Bid||36.35 x 900|
|Ask||37.80 x 1100|
|Day's Range||35.90 - 37.12|
|52 Week Range||30.05 - 61.25|
|Beta (3Y Monthly)||1.25|
|PE Ratio (TTM)||20.11|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.67|
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...
ROCKVILLE, Md., Feb. 12, 2019 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
Supernus Pharmaceuticals Inc NASDAQ NMS:SUPNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SUPN totaled $859 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and receive a $60 prize! I am going to run you through how I calculated Read More...
If you're interested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
ROCKVILLE, Md., Dec. 21, 2018 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents, weeks after results from trials testing the drug on children failed to impress investors. At daily doses of 200 mg and 400 mg, the drug, SPN-812, showed statistical significance in improvement in symptoms such as hyperactivity and lack of attention among 12-17 year olds, Supernus said. SPN-812 is a non-stimulant and belongs to the same class of medicines as Eli Lilly and Co's Strattera and Shire Plc's Intuniv.
“Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to Read More...
Supernus Pharmaceuticals, Inc. (SUPN) announced today that the United States Food and Drug Administration (FDA) has approved the Company’s supplemental new drug application (sNDA) for Oxtellar XR®. The application requested FDA approval to expand the indication for Oxtellar XR® beyond the current indication of adjunctive therapy in the treatment of partial-onset seizures in adults and in children 6 to 17 years of age. “We are pleased with the timely approval of the expanded indication for Oxtellar XR.
After a one-day break, stock indexes continued to drop Thursday, while the IBD 50 index of leading stocks fell into a bear market.
Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals. The drug, SPN-812, is a non-stimulant and belongs to the same class of medicine as Eli Lilly and Co's Strattera and Shire Plc's Intuniv. Analysts on average said that SPN-812 has failed to stand out from existing treatment options for ADHD.
Here's a roundup of top developments in the biotech space over the past 48 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 4) Johnson & Johnson (NYSE: JNJ ) Eli Lilly And Co (NYSE: ...
Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder met the main goal of reducing disorder symptoms in children in two late-stage studies. ...